These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 190609)

  • 21. The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals.
    Rodney G; Uhlendorf P; Maxwell RE
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):6-10. PubMed ID: 828263
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
    Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
    MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Summary of present data from a clinical trial of CI-719.
    Wilkening J; Schwandt P
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):90-3. PubMed ID: 1019158
    [No Abstract]   [Full Text] [Related]  

  • 24. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hypolipidemic drugs on serum lipoproteins.
    Carlson LA; Olsson AG
    Prog Biochem Pharmacol; 1979; 15():238-57. PubMed ID: 224397
    [No Abstract]   [Full Text] [Related]  

  • 26. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
    J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
    [No Abstract]   [Full Text] [Related]  

  • 27. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):76-81. PubMed ID: 176639
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
    J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P; Schwandt P
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():398-401. PubMed ID: 206058
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
    Bucalossi A; Buzzelli G; D'Alessandro A
    Clin Ter; 1979 Apr; 89(2):127-49. PubMed ID: 226307
    [No Abstract]   [Full Text] [Related]  

  • 31. Gemfibrozil for hyperlipidemia.
    Med Lett Drugs Ther; 1982 Jun; 24(612):59-60. PubMed ID: 6953310
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W; Kremer GJ; Müller D
    MMW Munch Med Wochenschr; 1975 Oct; 117(44):1783-6. PubMed ID: 171564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
    Gaertner U; Johannes KJ
    MMW Munch Med Wochenschr; 1976 Sep; 118(36):1127-30. PubMed ID: 184377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].
    Weisweiler P; Schwandt P
    Klin Wochenschr; 1977 Aug; 55(16):791-4. PubMed ID: 198601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current trends in the therapy of arteriosclerotic disease].
    Toscano S
    G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
    [No Abstract]   [Full Text] [Related]  

  • 37. Bile acid metabolism in hyperlipoproteinaemia.
    Hellström K; Einarsson K
    Clin Gastroenterol; 1977 Jan; 6(1):103-28. PubMed ID: 196796
    [No Abstract]   [Full Text] [Related]  

  • 38. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug therapy of hyperlipidemias].
    Wolfram G
    Wien Med Wochenschr; 1981; 131(13-14):333-8. PubMed ID: 7281700
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of clofibrate on the composition of very low and low density lipoprotein subfractions in type III hyperlipoproteinaemia.
    Ballantyne D; Ballantyne FC; Stromberg P; Third JL; Bedford DK
    Clin Chim Acta; 1978 Feb; 83(1-2):117-22. PubMed ID: 202421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.